Research programme: neurodegenerative disorders therapeutics - Herantis Pharma

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Herantis Pharma

Alternative Names: CDNF - Herantis Pharma; Conserved dopamine neurotrophic factor - Herantis Pharma; HER-901; MANF - Herantis Pharma; Mesencephalic astrocyte-derived neurotrophic factor - Herantis Pharma

Latest Information Update: 25 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Helsinki
  • Developer Herantis Pharma
  • Class Nerve growth factors; Neuroprotectants
  • Mechanism of Action Nerve growth factor receptor modulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 12 Jun 2017 Herantis Pharma plans to initiate a phase I/II trial for Parkinson's disease in Sweden and Finland in 3Q 2017
  • 23 May 2017 Herantis Pharma has patent protection for Mesencephalic astrocyte-derived neurotrophic factor (MANF) in USA
  • 25 Oct 2016 Herantis Pharma and Renishaw enter into a collaboration agreement for the first clinical study of cerebral dopamine neurotrophic factor in Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top